Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

19

Revenue 2017

Celgene

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Celgene's 2013 oncology sales performance.

Celgene

Dragonfly signs Celgene as partner for NK cell platform

Dragonfly signs Celgene as partner for NK cell platform

Extends presence in haemato-oncology and solid tumours. Immuno-oncology start-up Dragonfly Therapeutics has bagged a $24 million licensing deal from Celgene for two cancer therapeutics based on natural killer ... Celgene – one of the top blood cancer

UK’s genomics leadership attracts IQVIA investment, regardless of Brexit

UK’s genomics leadership attracts IQVIA investment, regardless of Brexit Roche, Celgene and Autolus.

UK life sciences gets some Brexit relief with £1.3bn sector deal

UK life sciences gets some Brexit relief with £1.3bn sector deal £1bn over the next five years, with sizeable support from Roche, IQVIA, Celgene and Autolus. ... £50m to expand its UK presence, including a new global headquarters, and Celgene has set aside £22m for a five-year drug discovery collaboration with

Dutch biotech Argenx claims $1.8bn licensing deal with J&J

Dutch biotech Argenx claims $1.8bn licensing deal with J&J It is being given in combination with Celgene’s Vidaza (azacitidine) and will look at escalating doses of Argenx’ drug, given intravenously, with a standard dose of Vidaza.

CAR-Ts take centre stage as ASH18 comes to a close

CAR-Ts take centre stage as ASH18 comes to a close Celgene and Juno’s JCARH125 also hit the mark in heavily pre-treated myeloma patients in the EVOLVE study – among 44 evaluable patients who had failed around seven lines of therapy,

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics